通过神经解剖学的规范建模揭示了阿尔茨海默病异质性
Flavia Loreto1, Serena Verdi2,3, Seyed Mostafa Kia4,5,6
1Department of Brain Sciences Faculty of Medicine Imperial College London London UK.
Alzheimer's & dementia (Amsterdam, Netherlands)
|March 15, 2024
概括
阿尔茨海默病 (AD) 脑缩是非常多样化的. 神经解剖学模型揭示了缩模式的个体差异,有助于理解疾病进展和临床相关性.
科学领域:
- 神经成像是一种神经成像.
- 神经学 神经学
- 生物统计学 生物统计学
背景情况:
- 阿尔茨海默病 (AD) 呈现出显著的异质性,可能导致诊断延迟.
- 神经解剖学规范建模提供了一种分析个体大脑变异和AD相关缩的方法.
研究的目的:
- 将神经解剖学规范建模应用于临床阿尔茨海默病队列.
- 研究大脑缩模式的个体差异及其与临床因素的相关性.
主要方法:
- 分析了来自86名AD患者和33072名健康对照者的磁共振成像 (MRI) 数据.
- 区域皮层厚度与规范性数据集进行了比较.
- 边缘大脑区域的数量和位置 (总异常值计数) 在个人和小组水平上得到量化.
主要成果:
- 上突显示出异常值的比例最高 (60%).
- 缩模式在患者之间几乎没有重叠,突出显示了异质性.
- 在非麻醉患者,晚期疾病患者和没有抑郁症状的患者中观察到较高的异常值计数.
- 粉样蛋白负担与总异常值计数相反相关.
结论:
- 阿尔茨海默病中的大脑缩的特点是相当多的异质性.
- 神经解剖学规范建模是探索AD患者个体脑缩模式及其临床相关性的宝贵工具.
相关概念视频
Alzheimer's Disease: Overview
475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186


